Janssen Pharmaceutica to expand production of Sirturo in Russia

Janssen Pharmaceutica, which is part of US healthcare giant Johnson & Johnson (NYSE: JNJ), plans to increase production of its Sirturo (bedaquiline) –an anti-tuberculosis drug – in Russia, at the capacities of a local drugmaker Pharmstandard, according to recent statements of the companies, reportsThe Pharma Letter’s local correspondent.

The drug is already produced by Janssen in Russia and it is planned that additional production capacities will be established at the facilities of Russian drugmaker Pharmstandard’s Ufa Vitamin Plant. The increase of production will allow Janssen to significantly expand the geography of supplies of Sirturo worldwide.

Details of the contract are not disclosed.